Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Yoshiro Itatani, Kenji Kawada, Takamasa Yamamoto, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 4, pp. 1232-1232
Open Access | Times Cited: 283

Showing 1-25 of 283 citing articles:

VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte, Daniel S. Chen, Napoleone Ferrara
Cell (2019) Vol. 176, Iss. 6, pp. 1248-1264
Open Access | Times Cited: 2048
Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation
Sen Guo, Chu‐Xia Deng
International Journal of Biological Sciences (2018) Vol. 14, Iss. 14, pp. 2083-2093
Open Access | Times Cited: 267
Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms
Jan Korbecki, Donata Simińska, Magdalena Gąssowska-Dobrowolska, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10701-10701
Open Access | Times Cited: 225
Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment
Yoshiro Itatani, Kenji Kawada, Yoshiharu Sakai
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 23, pp. 5822-5822
Open Access | Times Cited: 203
Targeting angiogenesis in oncology, ophthalmology and beyond
Yihai Cao, Róbert Langer, Napoleone Ferrara
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 476-495
Open Access | Times Cited: 148
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, et al.
JAMA Oncology (2021) Vol. 7, Iss. 3, pp. 386-386
Open Access | Times Cited: 145
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Jing Yang, Zhangsuo Liu
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 143
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 141
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Shujing Wang, Jingrui Wang, Zhiqiang Chen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 140
The Role of the VEGF Family in Coronary Heart Disease
Yan Zhou, Xueping Zhu, Hanming Cui, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 129
Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1
Qinglian He, Aihua Ye, Wei‐Biao Ye, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 119
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Morgane Bourhis, Juliette Palle, Isabelle Galy–Fauroux, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 115
A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions
Selvaraj Vimalraj
International Journal of Biological Macromolecules (2022) Vol. 221, pp. 1428-1438
Closed Access | Times Cited: 98
Mechanisms of chemotherapy resistance in ovarian cancer
Mylena Ortiz, Emma Wabel, Kerry Mitchell, et al.
Cancer Drug Resistance (2022)
Open Access | Times Cited: 77
Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy
Xiujuan Liu, Hong-Cheng Zhao, Su-Juan Hou, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106425-106425
Closed Access | Times Cited: 73
Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer
Fengliu Deng, Rui Zhou, Chuang Lin, et al.
Theranostics (2019) Vol. 9, Iss. 4, pp. 1001-1014
Open Access | Times Cited: 127
Tumor Neovascularization and Developments in Therapeutics
Yuki Katayama, Junji Uchino, Yusuke Chihara, et al.
Cancers (2019) Vol. 11, Iss. 3, pp. 316-316
Open Access | Times Cited: 111
The Endocrine Disruptor Bisphenol A (BPA) Exerts a Wide Range of Effects in Carcinogenesis and Response to Therapy
Shirin Hafezi, Wael M. Abdel‐Rahman
Current Molecular Pharmacology (2019) Vol. 12, Iss. 3, pp. 230-238
Open Access | Times Cited: 105
Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer
Eleni‐Kyriaki Vetsika, Aristeidis Koukos, Athanasios Κotsakis
Cells (2019) Vol. 8, Iss. 12, pp. 1647-1647
Open Access | Times Cited: 98
Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
Josh Wallsh, Ron P. Gallemore
Cells (2021) Vol. 10, Iss. 5, pp. 1049-1049
Open Access | Times Cited: 92
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
Suguru Kadomoto, Kouji Izumi, Atsushi Mizokami
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8530-8530
Open Access | Times Cited: 91
Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway
Fuqing Hu, Xuling Sun, Geng Li, et al.
Cell Death and Disease (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 88
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
Carolyn Haunschild, Krishnansu S. Tewari
Future Oncology (2019) Vol. 16, Iss. 7, pp. 225-246
Open Access | Times Cited: 83
Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells
Valdenizia R. Silva, Luciano de S. Santos, Rosane B. Dias, et al.
Cancer Communications (2021) Vol. 41, Iss. 12, pp. 1275-1313
Open Access | Times Cited: 77
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 3, pp. 675-675
Open Access | Times Cited: 76
Page 1 - Next Page

Scroll to top